ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Sorrento Exercises Exclusive Option Agreement With Texas A&M University for MPRO Inhibitors Against Sars-Cov-2 and all Variants of Concern
August 27, 2021Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced today that it has notified The Texas A&M University System ("TAMUS") of its exercise of the option to an exclusive license for the global development and commercialization of highly potent -
Anixa, OntoChem Announce Identification of Additional Covid-19 Compounds
August 18, 2020Anixa Biosciences announced that the company and its partner, OntoChem, have identified additional candidates through their in silico screening study.
Pharma Sources Insight January 2025
